Quretech Bio - defeats bacterial virulence
QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems.
New types of antibiotics to tackle resistant bacteria are urgently needed, yet there is an almost empty drug pipeline with few early stage drugs under development. Scientific and industrial communities must develop new antibiotic drugs, and there must be a drive towards developing novel antibiotics with alternative modes of action.